San Diego-based Exagen Diagnostics Inc. has a somewhat unique business model. It's aiming to both improve diagnostics and monitoring for autoimmune patients, but also to partner with biopharmas to promote better testing – and even to market related therapeutics to autoimmune specialists.

Glaxosmithkline plc has won FDA approval to market Nucala (mepolizumab) for use in children as young as 6 with severe eosinophilic asthma (EA). The therapy already had FDA approval as an add-on maintenance treatment for kids with the same condition ages 12 and older. Approval of the sBLA, submitted last November, catches the U.S. market up to the EU, where Nucala has been approved as an add-on treatment for children ages 6 to 17 since August 2018.

BOGOTA, Colombia – Argentina, hit by a challenging economic crisis, is struggling to supply vaccines to its population. The most recent shortages affect Menveo, a vaccine produced by Glaxosmithkline plc for preventing meningococcal disease.

Glaxosmithkline plc (GSK) and the direct-to-consumer genetic testing firm 23andme Inc. kicked off a four-year collaboration – with an option to extend into a fifth year – that includes a $300 million equity investment by the pharma player.